Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > Chuikyo Debate on FY2026 Drug Pricing Reform
Chuikyo Debate on FY2026 Drug Pricing Reform
-
Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead
January 19, 2026
-
Chuikyo OKs 3.5% Minimum NHI Price Hike, Sets Grace Period for New AG Pricing
January 19, 2026
-
Bosulif, 4 Other Drugs Escape April Re-Pricing as “Spillover” Scrapped; Lixiana, Entresto Brace for Cuts
January 19, 2026
-
Japan Sets New Pricing Rules for Conditionally Approved Regenerative Medicines, Starting with Elevidys
January 15, 2026
-
Gist of FY2026 Drug Pricing Reform Outline
December 26, 2025
-
Japan Puts CEA Expansion on Hold, Sets 6-Month “Technical Discussions”
December 26, 2025
-
Chuikyo OKs FY2026 Drug Pricing Reform Outline, Scraps “Spillovers” but Adds New Follow-Up Rules
December 26, 2025
-
Japan Ministers Agree to Scrap “Spillover” Rule, Plan Wider CEA Price Cuts
December 25, 2025
-
Chuikyo Backs Draft FY2026 Pricing Reform Outline, Rejects Key Industry Requests
December 15, 2025
-
Pharma Renews Call to Scrap “Spillover,” “Huge-Seller” Rules as FY2026 Talks Enter Final Stretch
December 11, 2025
-
2024 Reform Spurred New Development Activity, 20 Projects Entered Clinic: Industry Poll
December 11, 2025
-
Regenerative Medicine Group Accepts Deferred Debate on Market Expansion Re-Pricing
December 11, 2025
-
Wholesalers Urge Price Hikes on Sub-20-Yen Drugs as Negative Margins Mount
December 11, 2025
-
MHLW Floats Deducting Private-Practice Use for Re-Pricing, but Off-Cycle Cuts Possible; GLP-1 Eyed?
December 4, 2025
-
MHLW Proposes Pricing New AGs and Bio-AGs on Par with Originators
December 4, 2025
-
FY2026 Reform Roadmap Keeps Key Drug Pricing Issues on Ice, Snubs Many Industry Requests: Chuikyo
December 4, 2025
-
Average NHI-Market Price Gap Hits Fresh Record Low at 4.8%
December 3, 2025
-
Chuikyo Discusses Lower Prices for Low-Novelty Drugs, PMP Criteria, Re-Pricing
November 20, 2025
-
Chuikyo Split over How to Ease Negative Margins
November 20, 2025
-
Providers Urging Possible Price Measures over Packaging Misalignment
November 20, 2025
ページ
Japan’s Biological Raw Material Rules Enter Major Revision; Clarity on Benefits and Safety Holds Key
Japan is poised to make the most sweeping revision in eight years to the Standards for Biological Raw Materials —…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…